摘要
The world is currently facing a highly contagious and fatal pandemic caused by SARS-CoV-2,which is also the first pandemic caused by a coronavirus yet.As of 25 August 2020,the number of confirmed COVID-19 patients has exceeded 23,518,343 worldwide,with a death toll of over 810,492.1 To date,the greatest challenge we face is the incomplete knowledge of both SARS-CoV-2 and COVID-19,resulting in a lack of effective drugs and adequate treatment strategies.Despite various treatment options for critical COVID-19 patients,including extracorporeal membrane oxygenation,ventilation,tracheal intubation,circulatory support,and non-specific antiviral drugs,clinical outcomes are unsatisfactory.2 In particular,some mild or common COVID-19 patients experience sudden and rapid deterioration with the onset of fatal cytokine storm syndrome which cannot be treated by any conventional therapies.Therefore,from 2 February 2020 to 4 March 2020,the China National Health Commission has issued successively the 1st–7th editions of the Official Guidance of Diagnosis and Management for COVID-19 and formulated preliminary guidelines for the clinical application of convalescent plasma therapy(CPT)for critical COVID-19 patients.
